CN116322648A - 包封烟酰胺的胶束、以及含有包封烟酰胺的胶束的妊娠高血压综合征治疗用组合物 - Google Patents

包封烟酰胺的胶束、以及含有包封烟酰胺的胶束的妊娠高血压综合征治疗用组合物 Download PDF

Info

Publication number
CN116322648A
CN116322648A CN202180067172.9A CN202180067172A CN116322648A CN 116322648 A CN116322648 A CN 116322648A CN 202180067172 A CN202180067172 A CN 202180067172A CN 116322648 A CN116322648 A CN 116322648A
Authority
CN
China
Prior art keywords
nicotinamide
micelles
block copolymer
polyether
pregnancy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180067172.9A
Other languages
English (en)
Chinese (zh)
Inventor
H·卡布拉尔
宫崎拓也
P·陈
川岛直也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
University of Tokyo NUC
Original Assignee
Aska Pharmaceutical Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd, University of Tokyo NUC filed Critical Aska Pharmaceutical Co Ltd
Publication of CN116322648A publication Critical patent/CN116322648A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180067172.9A 2020-10-09 2021-10-08 包封烟酰胺的胶束、以及含有包封烟酰胺的胶束的妊娠高血压综合征治疗用组合物 Pending CN116322648A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-171414 2020-10-09
JP2020171414 2020-10-09
PCT/JP2021/037453 WO2022075470A1 (ja) 2020-10-09 2021-10-08 ニコチンアミド内包ミセル、及びニコチンアミド内包ミセルを含む妊娠高血圧症候群治療用組成物

Publications (1)

Publication Number Publication Date
CN116322648A true CN116322648A (zh) 2023-06-23

Family

ID=81126087

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180067172.9A Pending CN116322648A (zh) 2020-10-09 2021-10-08 包封烟酰胺的胶束、以及含有包封烟酰胺的胶束的妊娠高血压综合征治疗用组合物

Country Status (6)

Country Link
US (1) US20230301909A1 (https=)
EP (1) EP4226925A4 (https=)
JP (1) JPWO2022075470A1 (https=)
KR (1) KR20230084499A (https=)
CN (1) CN116322648A (https=)
WO (1) WO2022075470A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4485805A1 (en) 2023-06-29 2025-01-01 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Analog-to-digital converter

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030466A2 (en) * 2000-10-11 2002-04-18 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
WO2009065077A1 (en) * 2007-11-16 2009-05-22 Pharmain Corporation Cationic-core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP2015030721A (ja) * 2013-08-07 2015-02-16 国立大学法人東北大学 ニコチンアミドによる妊娠高血圧症候群、流産・早産、及び子宮内胎児発育遅延の改善
CN105801847A (zh) * 2016-03-16 2016-07-27 华东师范大学 一种用于抗肿瘤药物递送的助溶高分子载体及制备方法
CN109568268A (zh) * 2017-09-28 2019-04-05 中国科学院深圳先进技术研究院 胎盘靶向递送系统及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220257790A1 (en) * 2019-06-26 2022-08-18 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030466A2 (en) * 2000-10-11 2002-04-18 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
WO2009065077A1 (en) * 2007-11-16 2009-05-22 Pharmain Corporation Cationic-core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP2015030721A (ja) * 2013-08-07 2015-02-16 国立大学法人東北大学 ニコチンアミドによる妊娠高血圧症候群、流産・早産、及び子宮内胎児発育遅延の改善
CN105801847A (zh) * 2016-03-16 2016-07-27 华东师范大学 一种用于抗肿瘤药物递送的助溶高分子载体及制备方法
CN109568268A (zh) * 2017-09-28 2019-04-05 中国科学院深圳先进技术研究院 胎盘靶向递送系统及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEN XU 等: "pH-triggered charge-reversal and redox-sensitive drug-release polymer micelles codeliver doxorubicin and triptolide for prostate tumor therapy", INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 13, 8 November 2018 (2018-11-08), pages 7229 *

Also Published As

Publication number Publication date
US20230301909A1 (en) 2023-09-28
WO2022075470A1 (ja) 2022-04-14
EP4226925A1 (en) 2023-08-16
JPWO2022075470A1 (https=) 2022-04-14
EP4226925A4 (en) 2025-07-23
KR20230084499A (ko) 2023-06-13

Similar Documents

Publication Publication Date Title
EP1971622B1 (en) A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions
EP2359860B1 (en) Polymer micelle composition for treatment of resistant cancer cells
Wu et al. pH/redox dual-responsive amphiphilic zwitterionic polymers with a precisely controlled structure as anti-cancer drug carriers
EP2035488A1 (en) Micelles for drug delivery
JP6853924B2 (ja) 温度感受性重合体を用いた核酸の送達用ミセル組成物およびその製造方法
JP2011105792A (ja) ブロックコポリマー、ブロックコポリマー−金属錯体複合体、及びそれを用いた中空構造体キャリア
Zhang et al. Poly (ethylene glycol) shell-sheddable TAT-modified core cross-linked nano-micelles: TAT-enhanced cellular uptake and lysosomal pH-triggered doxorubicin release
CN116322648A (zh) 包封烟酰胺的胶束、以及含有包封烟酰胺的胶束的妊娠高血压综合征治疗用组合物
CN111205411B (zh) 一种血管和肿瘤增强大分子磁共振对比剂及其制备方法和用途
Pan et al. Dendron-polymer hybrid mediated anticancer drug delivery for suppression of mammary cancer
Rostami et al. Peptide-conjugated PEGylated PAMAM as a highly affinitive nanocarrier towards HER2-overexpressing cancer cells
Chen et al. Propionate-functionalized chitosan hydrogel nanoparticles for effective oral delivery of insulin
KR20150132235A (ko) 폴리알킬렌 산화물 발레르산염 헤모글로빈 접합체
CN107224589B (zh) 一种输送抗体用于肿瘤免疫治疗的mr成像聚合物胶束及其制备方法
US9968633B2 (en) Stimuli responsive compositions for iron chelation
JP2019142813A (ja) 細胞増殖抑制用医薬組成物
WO2023136364A1 (ja) サイトカイン内包高分子ミセル
KR101788610B1 (ko) 의약용 단백질의 지속방출을 위한 약물전달체 및 이의 제조방법
TW201008946A (en) Camptothecin polymer derivative and uses of the same
CN117003820A (zh) 一种基于含巯基的两性离子多肽修饰的可降解两亲性分子、纳米胶束及其制备方法
CN114652747B (zh) 一种双前药骨架聚合物PCPt、其纳米颗粒及其制备方法和应用
CN116265015A (zh) 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及其用途
WO2026037001A1 (zh) 基于谷胱甘肽响应微环境活性氧实现靶向药物递送的载体系统及其制备方法和应用
WO2020051541A1 (en) Nanoparticulate drug delivery systems
CN115845076A (zh) 一种两性离子聚合物-胰岛素偶联物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230623